首页> 外文OA文献 >Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
【2h】

Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?

机译:卵巢恶性肿瘤算法的风险是否提供比HE4和CA125在波兰女性的侧腹肿瘤的预设分化中的更好的诊断性能?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aim. This study compared the diagnostic performance of the Risk of Ovarian Malignancy Algorithm (ROMA) and HE4 and CA125 for the presurgical differentiation of adnexal tumors. Material and Methods. This prospective study included 302 patients admitted for surgical treatment due to adnexal tumors. The ROMA was calculated depending on CA125, HE4, and menopausal status. Results. Fifty patients were diagnosed with malignant disease. In the differentiation of malignant from nonmalignant adnexal tumors, the area under curve (AUC) was higher for ROMA and HE4 than that for CA125 in both the premenopausal and postmenopausal subgroups. In the differentiation of stage I FIGO malignancies and epithelial ovarian cancer from nonmalignant pathologies, the AUC of HE4 and ROMA was higher than that of CA125. The ROMA performed significantly better than CA125 in the differentiation of all malignancies and differentiation of stage I FIGO malignancies from nonmalignant pathologies (p=0.043 and p=0.025, resp.). There were no significant differences between the ROMA and the tumor markers for any other variants. Conclusions. The ROMA is more useful than CA125 for the differentiation of malignant (including stage I FIGO) from nonmalignant adnexal tumors. It is also as useful as HE4 and CA125 for the differentiation of epithelial ovarian cancer from nonmalignant adnexal tumors.
机译:目的。该研究比较了卵巢恶性算法(ROMA)和HE4和CA125风险的诊断性能,用于附带肿瘤的前静脉分化。材料与方法。这项前瞻性研究包括由于侧前肿瘤而入侵的302名患者。根据CA125,HE4和更长期状态计算ROMA。结果。五十名患者被诊断出患有恶性疾病。在来自非空心内存肿瘤的恶性的分化中,曲线(AUC)下的面积比前肢和绝经后亚组中的CA125的roma和He4更高。在I阶段的差异化中,来自非开始病理的恶性恶性肿瘤和上皮性卵巢癌,HE4和ROMA的AUC高于CA125的AUC。罗姆人在差异的情况下显着优于Ca125,在非开始病理学的所有恶性肿瘤和阶段恶性肿瘤的分化中(p = 0.043和p = 0.025,REAC)。罗姆与任何其他变体的肿瘤标志物之间没有显着差异。结论。 ROMA比CA125更有用,对于来自非开始的侧内肿瘤的恶性(包括阶段I FICO)的分化更有用。它也可用作HE4和CA125,用于从非开始的侧鼻肿瘤分化上皮卵巢癌的分化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号